Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Q1 2025 Management View CEO Daniel O'Day highlighted a 4% growth in the base business excluding Veklury, led by a 6% ...

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

He said that in Africa, the Purpose 1 Trial was 100% effective with none of the 2,134 women given Lenacapavir becoming HIV ...